The Moment That Changed the Field
In January 2024, Noland Arbaugh, paralysed from the shoulders down, became the first human to receive Elon Musk's Neuralink N1 implant. Within weeks of his recovery he was playing online chess using only his thoughts; within months he was streaming about daily life with a chip embedded in his motor cortex. For a field that had spent decades as a research curiosity, this did for brain-computer interfaces roughly what AlphaGo did for AI in 2016 - it converted an abstract research area into something the public understood was actually, concretely happening to a real person.
What Neuralink's Device Actually Does
The N1 implant uses a robotic surgeon to insert over a thousand ultra-thin electrode threads into the brain's motor cortex, reading the electrical signals generated when a patient thinks about movement and translating them into cursor control on a screen. Early implants suffered from thread retraction - several threads shifted out of their optimal position, reducing the number of electrodes capturing usable signal - a real technical setback that Neuralink has since partially addressed through both software adaptation and revised surgical technique. By early 2026, the company's PRIME feasibility study had implanted roughly 21 participants across the US, UK, Canada, and the UAE, accumulating thousands of hours of real-world home use for cursor and keyboard control, with sister trials extending toward robotic arm control and speech restoration.
The Competitor Taking a Completely Different Approach
Neuralink is not the only serious player, and its most interesting competitor, Synchron, has taken a fundamentally different technical path. Rather than open-skull surgery, Synchron's Stentrode device is delivered through a blood vessel via an incision in the neck - similar to how cardiologists place a cardiac stent - and threaded up to sit against the motor cortex without ever opening the skull at all. The trade-off is real: Stentrode uses just sixteen electrodes compared to Neuralink's thousand-plus, meaning lower signal resolution and slower, less precise cursor control. But its safety profile has been strong, with six implanted patients in its COMMAND study and zero serious adverse events reported, and a $200 million funding round closed in late 2025 to support a planned pivotal trial aimed at the first-ever premarket approval application for a permanently implanted communication BCI.
A Genuinely Crowded, Serious Field
Beyond these two, the competitive field is real and substantive rather than a two-horse race. Precision Neuroscience's Layer 7 uses a flexible, film-like electrode array. Blackrock Neurotech's Utah Array has been in clinical use since 2004, giving it by far the longest track record of any BCI platform. Paradromics' Connexus targets high-bandwidth applications aimed at restoring speech at speeds approaching natural conversation for patients with locked-in syndrome. The US brain-computer interface market was valued at roughly $1.21 billion in 2025 and is projected to reach $5.18 billion by 2035 - genuine, sustained investment rather than a speculative bubble around a single company.
What's Real Today Versus What's Still Years Away
Everything described above - cursor control, basic communication, early robotic arm control - is aimed squarely at patients with severe paralysis or locked-in syndrome, where even modest restored capability represents a life-changing improvement in independence. That's a meaningfully different, and considerably nearer-term, goal than the "healthy people upgrading their brains" vision Musk has floated for Neuralink's longer-term future. Neuralink's next-generation Blindsight device, aimed at restoring vision via a cortical implant, received FDA Breakthrough Device designation and remains in earlier-stage trials, with human vision restoration still measured in years rather than months.
The Honest Bottom Line
Brain-computer interfaces have moved decisively from theoretical research to genuine, functioning clinical reality for a specific, serious patient population - that part isn't hype. What remains further off is the more speculative, mainstream-consumer version of this technology sometimes implied by company marketing. For now, the real story is a competitive, well-funded field of genuinely different technical approaches, each finding early success with patients who have the most to gain from even modest capability - which is arguably a better, steadier foundation for the technology's future than a single dramatic breakthrough would be.
